Additional file 1: Figure S1. Prognostic impact of TFAP2D expression in all cancers defined by the Gleason score. a) Impact of negative and positive TFAP2D expression as compared to the classical Gleason score categories. b-h) Impact of negative and positive TFAP2D expression as compared to the quantitative Gleason score categories defined by subsets of cancers with b) ≤5% Gleason 4 patterns, c) 6–10% Gleason 4 patterns, d) 11–20% Gleason 4 patterns, e) 21–30% Gleason 4 patterns, f) 31–49% Gleason 4 patterns, g) 50–60% Gleason 4 patterns, h) ≥61% Gleason 4 patterns.